Neuropeptide Alterations in Mood Disorders
Paul M. Plotsky, Michael J. Owens, and Charles B. Nemeroff
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia 30322.
1. Ågren H, Lundqvist G. Low levels of somatostatin in human CSF mark depressive episodes. Psychoneuroendocrinology 1984;9:233–248.
2. Altemus M, Pigott T, L'Heureux F, et al. CSF somatostatin in obsessive-compulsive disorder. Am J Psychiatry 1993;150:460–464.
3. Amsterdam JD, Maislin G, Winokur A, Berwish N, Kling M, Gold P. The oCRH test before and after clinical recovery from depression. J Affect Dis 1988;14:213–222.
4. Amsterdam JD, Marinelli DL, Arger P, Winokur A. Assessment of adrenal gland volume by computed tomography in depressed patients and healthy volunteers: a pilot study. Psychiatry Res 1987; 21:189–197.
5. Arato M, Banki CM, Bissette G, Nemeroff CB. Elevated CSF CRF in suicide victims. Biol Psychiatry 1989;25:355–359.
6. Arnold MA, Reppert SM, Rorstad OP, et al. Temporal patterns of somatostatin immunoreactivity in the cerebrospinal fluid of the rhesus monkey: effect of environmental lighting. J Neurosci 1982; 2:674–680.
7. Banki CM, Bissette G, Arato M, Nemeroff CB. Elevation of immunoreactive CSF TRH in depressed patients. Am J Psychiatry 1988; 145:1526–1531.
8. Banki CM, Karmacsi L, Bissette G, Nemeroff CB. Cerebrospinal fluid neuropeptides in mood disorder and dementia. J Affect Dis 1992;25:39–45.
9. Banki CM, Karmacsi L, Bissette G, Nemeroff CB. CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 1992;2:107–113.
10. Bartalena L, Placidi GF, Martino E, et al. Nocturnal serum thyrotropin (TSH) surge and the TSH response to TSH-releasing hormone: dissociated behavior in untreated depressives. J Clin Endocrinol Metab 1990;71(3):650–655.
11. Berrettini WH, Nurnberger JL Jr, Zerbe RL, Gold PW, Chrousos GP, Tomai T. CSF neuropeptides in euthymic bipolar patients and controls. Br J Psychiatry 1987;150:208–212.
12. Bissette G, Widerlöv E, Walléus H, et al. Alterations in cerebrospinal fluid concentrations of somatostatinlike immunoreactivity in neuropsychiatric disorders. Arch Gen Psychiatry 1986;43:1148–1151.
13. Black PMcL, Ballantine HT Jr, Carr DB, Beal MF, Martin JB. Beta-endorphin and somatostatin concentrations in the ventricular cerebrospinal fluid of patients with affective disorder. Biol Psychiatry 1986;21:1075–1077.
14. Bowen DM, Najlerahim A, Procter AW, Francis PT, Murphy E. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc Natl Acad Sci USA 1989;86:9504–9508.
15. Charlton BG, Leake A, Wright C, et al. Somatostatin content and receptors in the cerebral cortex of depressed and control subjects. J Neurol Neurosurg Neuropsychiatry 1988;51:719–721.
16. Dallman MF. Regulation of adrenocortical function following stress. In: Brown MR, Koob GF, Rivier C, eds. Stress neurobiology and neuroendocrinology. New York: Marcel Dekker; 1991:173–192.
17. Davis KL, Davidson M, Yang R-K, et al. CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects. Biol Psychiatry 1988;24:710–712.
18. DeBellis MD, Gold PW, Geracioti TD, Listwak S, Kling MA. Fluoxetine significantly reduces CSF CRH and AVP concentrations in patients with major depression. Am J Psychiatry 1993;150:656–657.
19. Doran AR, Rubinow DR, Roy A, Pickar D. CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients. Arch Gen Psychiatry 1986;43:365–369.
20. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev 1990;15:71–100.
21. Duval F, Macher JP, Mokrani MC. Difference between evening and morning thyrotropin response to protirelin in major depressive episode. Arch Gen Psychiatry 1990;47:443–448.
22. Eccles J. Chemical transmission and Dale's principle. In: Hökfelt T, Fuxe K, Pernow B, eds. Progress in Brain Research. Amsterdam: Elsevier; 1986:3–13.
23. Fossey MD, Lydiarel RB, Larara MT, Bissette G, Nemeroff CB, Balleyer JC. CSF thyrotropin-releasing hormone in patients with anxiety disorders. Biol Psychiatry 1990;27(Suppl):167A.
24. Garrick NA, Hill JL, Szele FG, Tomai TP, Gold PW, Murphy DL. Corticotropin-releasing factor: a marked circadian rhythm in primate cerebrospinal fluid peaks in the evening and is inversely related to the cortisol circadian rhythm. Endocrinology 1987; 121:1329–1334.
25. Gerner RH, Yamada T. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res 1982;238:298–302.
26. Gertz BJ, Cantreras LN, McComb DJ, Kovacs K, Tyrrell JB, Dallman MF. Chronic administration of corticotropin-releasing factor increases pituitary corticotroph number. Endocrinology 1987; 120:381–388.
27. Gold MS, Pottash AL, Extein I. Hypothyroidism and depression. Evidence from complete thyroid function evaluation. JAMA 1981;245(19):919–922.
28. Gold PW, Loriaux DL, Roy A, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. New Engl J Med 1986;314:1329–1335.
29. Haggerty JJ Jr, Garbutt JC, Evans DL, Simon JS, Nemeroff CB. Subclinical hypothyroidism: a review of neuropsychiatric aspects. Int J Psychiatry Med 1990;20:193–208.
30. Hauger RL, Lorang M, Irwin M, Aguilera G. CRF receptor regulation and sensitization of ACTH responses to acute ether stress during chronic intermittent immobilization stress. Brain Res 1990; 532:34–40.
31. Henn FA, McKinney WT. Animal models in psychiatry. In: Meltzer HY, ed. Psychopharmacology: the third generation. New York: Raven Press; 1987:687–696.
32. Hökfelt T. Neuropeptides in perspective: the last ten years. Neuron 1991;7:867–879.
33. Holsboer F, Gerken A, Stalla GK, Muller OA. Blunted aldosterone and ACTH release after human corticotropin-releasing factor administration in depressed patients. Am J Psychiatry 1987;144:229–231.
34. Howland RH. Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. J Clin Psychiatry 1993;54:47–54.
35. Joffee RT, Sokolov TH. Thyroid hormones, the brain, and affective disorders. Crit Rev Neurobiol 1994;8:45–63.
36. Jolkkonen J, Lepola U, Bissette G, Nemeroff CB, Riekkinen P. CSF corticotropin-releasing factor is not affected in panic disorder. Biol Psychiatry 1993;33:136–138.
37. Kakigi T, Maeda K, Kaneda H, Chihara K. Repeated administration of antidepressant drugs reduces regional somatostatin concentrations in rat brain. J Affect Dis 1992;25(4):215–220.
38. Kaye WH, Gwirtsman HE, George DT, et al. Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa; relation to state of nutrition, adrenal function, and intensity of depression. J Clin Endocrinol Metab 1987;64:203–208.
39. Kaye WH, Rubinow D, Gwirtsman HE, George DT, Jimerson DC, Gold PW. CSF somatostatin in anorexia nervosa and bulimia: relationship to the hypothalamic pituitary-adrenal cortical axis. Psychoneuroendocrinology 1988;13:265–272.
40. Kirkegaard C. The thyrotropin response to thyrotropin-releasing hormone in endogenous depression. Psychoneuroendocrinology 1981;6:189–212.
41. Kling MA, Rubinow DR, Doran AR, et al. Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression: relationship to indicies of corticotropin-releasing hormone and cortisol secretion. Neuroendocrinology 1993;57:79–88.
42. Koob GF, Heinrichs SC, Pich EM, et al. The role of CRF in behavioral responses to stress. In: Chadwick DJ, Marsh J, Ackrill K, eds. CIBA Foundation Symposium #172. New York: John Wiley; 1993:277–295.
43. Krishnan KRR. Pituitary and adrenal changes in depression. Psychiatric Ann 1993;23:671–675.
44. Krishnan KRR, Rayasam K, Reed DR, et al. The corticotropin-releasing factor stimulation test in patients with major depression: relationship to dexamethasone suppression test results. Depression 1993;1:133–136.
45. Kruesi MJP, Swedo S, Leonard H, Rubinow DR, Rapoport JL. CSF somatostatin in childhood psychiatric disorders: a preliminary investigation. Psychiatry Res 1990;33:277–284.
46. Kubek MJ, Sattin A. Effect of electroconvulsive shock on the content of thyrotropin-releasing hormone in rat brain. Life Sci 1984; 34:1149–1152.
47. Langer G, Koinig G, Hatzinger R, et al. Response of thyrotropin to thyrotropin-releasing hormone as predictor of treatment outcome. Arch Gen Psychiatry 1986;43:861–868.
48. Loosen PT. Pituitary-thyroid axis in affective disorders. In: Meltzer HY, ed. Psychopharmacology: the third generation. New York: Raven Press; 1987:629–636.
49. Maeda K, Yoshimoto Y, Yamadori A. Blunted TSH and unaltered PRL responses to TRH following repeated administration of TRH in neurologic patients: a replication of neuroendocrine features of major depression. Biol Psychiatry 1993;33:277–283.
50. Meaney MJ, Mitchell JB, Aitken DH, et al. The effects of neonatal handling on the development of the adrenocortical response to stress: implications for neuropathology and cognitive deficits in later life. Psychoneuroendocrinology 1991;16:85–103.
51. Molchan SE, Lawlor BA, Hill JL, et al. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol Psychiatry 1991;29:1110–1118.
52. Nemeroff CB. The relevace of thyrotropin-releasing hormone to psychiatric disorders. In: Nemeroff CB, ed. Progress in psychiatry, neuropeptides and psychiatric disease. Washington DC: American Psychiatric Association Press; 1990:15–28.
53. Nemeroff CB, Bissette G, Akil H, Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy: corticotropin-releasing factor, b-endorphin and somatostatin. Br J Psychiatry 1991;158:59–63.
54. Nemeroff CB, Bissette G, Martin JB, et al. Effect of chronic treatment with thyrotropin-releasing hormone (TRH) or an analog of TRH (linear b-alanine TRH) on the hypothalamic-pituitary-thyroid axis. Neuroendocrinology 1980;30:193–199.
55. Nemeroff CB, Krishnan KRR, Reed D, Leder R, Beam C, Dunnick NR. Adrenal gland enlargement in major depression: a computed tomography study. Arch Gen Psychiatry 1992;49:384–387.
56. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin-releasing factor (CRF) binding sites in the frontal cortex of suicides. Arch Gen Psychiatry 1988;45:577–579.
57. Nemeroff CB, Widerlov E, Bissette G, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342–1344.
58. Owens MJ, Nemeroff CB. The physiology and pharmacology of corticotropin releasing factor. Pharmacol Rev 1992;43:425–473.
59. Pepin MC, Pothier F, Barden N. Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol Pharmacol 1992;42(6):991–995.
60. Plotnikoff NP, Prange AJ Jr, Breese GR, Anderson MS, Wilson IC. Thyrotropin releasing hormone: enhancement of DOPA activity by a hypothalamic hormone. Science 1972;178:417–418.
61. Plotsky PM. Pathways to the secretion of ACTH: a view from the portal. J Neuroendocrinol 1991;3:1–9.
62. Plotsky P, Meaney M. Early postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content, and stress-induced release in adult rats. Mol Brain Res 1993;18:195–200.
63. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149(8):999–1010.
64. Post PM. Models for the impact of affective illness on gene expression. Clin Neurosci 1993;1:129–138.
65. Post RM, Gold P, Rubinow DR, Ballenger JC, Bunney WE, Goodwin FK. Peptides in cerebrospinal fluid of neuropsychiatric patients: an approach to central nervous system peptide function. Life Sci 1982;31:1–15.
66. Post RM, Weiss SRB. Endogenous biochemical abnormalities in affective illness: therapeutic versus pathogenic. Biol Psychiatry 1992;32:469–484.
67. Risch SC, Lewine RJ, Jewart RD, et al. Relationship between cerebrospinal fluid peptides and neurotransmitters in depression. In: Risch SC, ed. Central nervous system peptide mechanisms in stress and depression. Washington DC: American Psychiatric Press; 1991:93–103.
68. Rothschild AJ. The dexamethasone suppression test in psychiatric disorders. Psychiatric Ann 1993;23:662–670.
69. Roy A, Bissette G, Nemeroff CB. Cerebrospinal fluid thyrotropin-releasing hormone concentrations in alcoholics and normal controls. Biol Psychiatry 1990;28:767–772.
70. Roy-Byrne PP, Uhde TW, Post RM, Gallucci W, Chrousos GP, Gold PW. The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 1986;143:896–899.
71. Rubin RT, Phillips JJ. Adrenal gland enlargement in major depression [letter]. Arch Gen Psychiatry 1993;50:833–835.
72. Rubinow DR. Cerebrospinal fluid somatostatin and psychiatric illness. Biol Psychiatry 1986;21:341–365.
73. Rubinow DR, Gold PW, Post RM. CSF somatostatin in affective illness. Arch Gen Psychiatry 1983;40:409–412.
74. Rubinow DR, Post RM, Gold PW, Ballenger JC, Reichlin S. Effects of carbamazepine on cerebrospinal somatostatin. Psychopharmacology 1985;85:210–213.
75. Russ MJ, Ackerman SH. Antidepressant treatment response in depressed hypothyroid patients. Hosp Community Psychiatry 1989; 40:954–956.
76. Sapolsky RM, Plotsky PM. Hypercortisolism and its possible neural basis. Biol Psychiatry 1990;27:937–952.
77. Schlesser MA, Rush AJ, Fairchild C, Crowley G, Orsulak P. The thyrotropin-releasing hormone stimulation test: a methodological study. Psychiatry Res 1983;9:59–67.
78. Shelton RC, Winn S, Ekhatore N, Loosen PT. The effects of antidepressants on the thyroid axis in depression. Biol Psychiatry 1993;33:120–126.
79. Smith MA, Davidson J, Ritchie JC, et al. The corticotropin-releasing hormone test in patients with post-traumatic stress disorder. Biol Psychiatry 1989;26:349–355.
80. Sorensen KV. Rapid post-mortem decomposition of the somatostatin cells in human brain. An immunohistochemical examination. Biomed Pharmacother 1984;38:458–461.
81. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 1992;30(6):3378–3386.
82. Sunderland T, Rubinow DR, Tariot PN, et al. CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects. Am J Psychiatry 1987;144:1313–1316.
83. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin of b-endorphin. Science 1981;213:1394–1397.
84. Whybrow PC, Prange AJ. A hypothesis of thyroid-catecholamine receptor interaction. Arch Gen Psychiatry 1981;38:106–113.
85. Young EA, Watson SJ, Kotun J, et al. b-lipotropin/b-endorphin response to low-dose ovine corticotropin releasing factor in endogenous depression. Arch Gen Psychiatry 1990;47:449–457.
86. Zis KD, Zis A. Increased adrenal weight in victims of violent suicide. Am J Psychiatry 1987;144:1214–1215.